CN106687456B - 可溶性鸟苷酸环化酶活化剂及它们的用途 - Google Patents

可溶性鸟苷酸环化酶活化剂及它们的用途 Download PDF

Info

Publication number
CN106687456B
CN106687456B CN201580050717.XA CN201580050717A CN106687456B CN 106687456 B CN106687456 B CN 106687456B CN 201580050717 A CN201580050717 A CN 201580050717A CN 106687456 B CN106687456 B CN 106687456B
Authority
CN
China
Prior art keywords
pyridin
piperidine
carboxylic acid
piperidin
difluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580050717.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN106687456A (zh
Inventor
A.M.J.布洛特
N.多迪克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN106687456A publication Critical patent/CN106687456A/zh
Application granted granted Critical
Publication of CN106687456B publication Critical patent/CN106687456B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CN201580050717.XA 2014-09-19 2015-09-18 可溶性鸟苷酸环化酶活化剂及它们的用途 Active CN106687456B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052537P 2014-09-19 2014-09-19
US62/052,537 2014-09-19
PCT/IB2015/057219 WO2016042536A1 (en) 2014-09-19 2015-09-18 Novel soluble guanylate cyclase activators and their use

Publications (2)

Publication Number Publication Date
CN106687456A CN106687456A (zh) 2017-05-17
CN106687456B true CN106687456B (zh) 2019-12-03

Family

ID=54238488

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580050717.XA Active CN106687456B (zh) 2014-09-19 2015-09-18 可溶性鸟苷酸环化酶活化剂及它们的用途

Country Status (21)

Country Link
US (2) US9938260B2 (https=)
EP (1) EP3194384A1 (https=)
JP (3) JP6678656B2 (https=)
KR (1) KR20170054508A (https=)
CN (1) CN106687456B (https=)
AU (1) AU2015319724B2 (https=)
BR (1) BR112017005660A2 (https=)
CA (1) CA2961745A1 (https=)
CL (1) CL2017000640A1 (https=)
CO (1) CO2017002506A2 (https=)
CR (1) CR20170102A (https=)
DO (1) DOP2017000073A (https=)
EA (1) EA033697B1 (https=)
IL (1) IL251094A0 (https=)
MA (1) MA40583A (https=)
MX (1) MX2017003621A (https=)
PE (1) PE20170937A1 (https=)
PH (1) PH12017500481A1 (https=)
SG (1) SG11201701915TA (https=)
WO (1) WO2016042536A1 (https=)
ZA (1) ZA201701835B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102352388B1 (ko) 2014-02-06 2022-01-17 헵테얼즈 테라퓨틱스 리미티드 무스카린성 m1 수용체 및/또는 m4 수용체 작용제로서 바이사이클릭 아자 화합물
MA39484A (fr) 2014-09-19 2016-03-24 Bayer Pharma AG Indazoles à substituants benzyle utilisés comme inhibiteurs de bub1
EA033697B1 (ru) * 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
JP7314173B2 (ja) 2018-04-30 2023-07-25 バイエル アクチェンゲゼルシャフト 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用
CA3100096A1 (en) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
EP4536205A1 (en) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071504A1 (en) * 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
CN101553206A (zh) * 2006-11-09 2009-10-07 爱尔康研究有限公司 用于药物递送的水不溶性聚合物基质
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
CN102414194A (zh) * 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
DE102009012314A1 (de) * 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
JP5636296B2 (ja) 2011-01-20 2014-12-03 公益財団法人微生物化学研究会 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体
EA033697B1 (ru) * 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553206A (zh) * 2006-11-09 2009-10-07 爱尔康研究有限公司 用于药物递送的水不溶性聚合物基质
WO2009071504A1 (en) * 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
CN102414194A (zh) * 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂

Also Published As

Publication number Publication date
CA2961745A1 (en) 2016-03-24
IL251094A0 (en) 2017-04-30
JP2017527602A (ja) 2017-09-21
AU2015319724A1 (en) 2017-04-06
JP2020105189A (ja) 2020-07-09
BR112017005660A2 (pt) 2017-12-19
PE20170937A1 (es) 2017-07-13
PH12017500481A1 (en) 2017-08-07
US20180194756A1 (en) 2018-07-12
EA033697B1 (ru) 2019-11-18
MA40583A (fr) 2016-03-24
EP3194384A1 (en) 2017-07-26
ZA201701835B (en) 2018-12-19
WO2016042536A1 (en) 2016-03-24
SG11201701915TA (en) 2017-04-27
CL2017000640A1 (es) 2017-10-06
EA201790655A1 (ru) 2017-08-31
CO2017002506A2 (es) 2017-07-28
US20170305888A1 (en) 2017-10-26
MX2017003621A (es) 2017-07-14
AU2015319724B2 (en) 2018-05-10
KR20170054508A (ko) 2017-05-17
CN106687456A (zh) 2017-05-17
CR20170102A (es) 2017-07-17
US10472350B2 (en) 2019-11-12
JP6908747B2 (ja) 2021-07-28
US9938260B2 (en) 2018-04-10
JP6678656B2 (ja) 2020-04-08
DOP2017000073A (es) 2017-04-16
JP2021155450A (ja) 2021-10-07

Similar Documents

Publication Publication Date Title
CN106687456B (zh) 可溶性鸟苷酸环化酶活化剂及它们的用途
CN104918934B (zh) 3‑取代的吡唑及其作为dlk抑制剂的用途
WO2020135771A1 (zh) 杂环类化合物、中间体、其制备方法及应用
WO2020147739A1 (zh) 溶血磷脂酸受体拮抗剂及其制备方法
CN111601799A (zh) 作为Il-17调节剂的稠合咪唑衍生物
AU2014316690B2 (en) Novel soluble guanylate cyclase activators and their use
WO2023072273A1 (zh) 作为cbl-b抑制剂的并环化合物
WO2021139595A1 (zh) RORγt抑制剂及其制备方法和用途
CN112135825A (zh) 血浆激肽释放酶抑制剂及其用途
TW201605795A (zh) 經取代磺醯胺化合物
TW201625586A (zh) 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
KR20170035993A (ko) 가용성 구아닐레이트 사이클라제의 활성제로서의 헤테로사이클릭 카복실산
CN103459382B (zh) 用于抑制pask的杂环化合物
TW201625601A (zh) 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
CN108779119A (zh) 嘧啶及其变体、及其用途
CN111479814A (zh) 作为h-pgds抑制剂的稠合的吡啶
WO2019185046A1 (zh) 四元内酰胺类化合物及其药学用途
CN101160128B (zh) 含有吲唑衍生物作为有效成分的视网膜神经细胞保护剂
CN109476637B (zh) 杂环脯氨酰胺衍生物
CN109563033B (zh) 脂族脯氨酰胺衍生物
KR20260030165A (ko) 헤테로 방향족 포름아미드 화합물 및 이의 의학적 응용
WO2021139599A1 (zh) RORγt抑制剂及其制备方法和用途
HK40041774B (zh) 溶血磷脂酸受体拮抗剂及其制备方法
CN105980373A (zh) 新的可溶性鸟苷酸环化酶活化剂及它们的用途
HK40048952B (zh) 杂环类化合物、中间体、其制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: Steve Niki

Patentee after: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT Ltd.

Country or region after: United Kingdom

Address before: British Meader Sykes

Patentee before: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT Ltd.

Country or region before: United Kingdom

CP03 Change of name, title or address